Levetiracetam: a comprehensive review (Q37688063)

22 August 2017

1 reference

title

Levetiracetam: a comprehensive review (English)

1 reference

22 August 2017

1 reference

Amy Z Crepeau

1

1 reference

22 August 2017

David M Treiman

series ordinal

2

1 reference

22 August 2017

publication date

1 February 2010

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

159-171

1 reference

Epidemiology of idiopathic generalized epilepsies

22 August 2017

cites work

1 reference

Channelopathies as a genetic cause of epilepsy

21 January 2018

1 reference

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

21 January 2018

1 reference

Levetiracetam in absence epilepsy.

21 January 2018

1 reference

Discovery of antiepileptic drugs

21 January 2018

1 reference

Early identification of refractory epilepsy

21 January 2018

1 reference

Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data.

21 January 2018

1 reference

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

21 January 2018

1 reference

Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug

21 January 2018

1 reference

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

21 January 2018

1 reference

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes

21 January 2018

1 reference

Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)

21 January 2018

1 reference

SV2A and SV2B function as redundant Ca2 regulators in neurotransmitter release

21 January 2018

1 reference

Levetiracetam inhibits the high-voltage-activated Ca(2 ) current in pyramidal neurones of rat hippocampal slices

21 January 2018

1 reference

Selective blockade of N-type calcium channels by levetiracetam

21 January 2018

1 reference

Levetiracetam reduces caffeine-induced Ca2 transients and epileptiform potentials in hippocampal neurons

21 January 2018

1 reference

The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2 ]I increase induced by ATP and bradykinin in PC12 cells

21 January 2018

1 reference

The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents

21 January 2018

1 reference

Development of tolerance to levetiracetam in rats with chronic epilepsy

21 January 2018

1 reference

Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy

21 January 2018

1 reference

Clinical pharmacokinetics of levetiracetam

21 January 2018

1 reference

Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat.

21 January 2018

1 reference

A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain

21 January 2018

1 reference

Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog.

21 January 2018

1 reference

Dynamic changes of ictal high-frequency oscillations in neocortical epilepsy: using multiple band frequency analysis

21 January 2018

1 reference

Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein

21 January 2018

1 reference

Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).

21 January 2018

1 reference

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

21 January 2018

1 reference

Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice

21 January 2018

1 reference

Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis

21 January 2018

1 reference

Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model

21 January 2018

1 reference

Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.

21 January 2018

1 reference

Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis

21 January 2018

1 reference

Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam

21 January 2018

1 reference

Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures

21 January 2018

1 reference

Levetiracetam in the treatment of infantile spasms

21 January 2018

1 reference

Levetiracetam monotherapy in newly diagnosed cryptogenic West syndrome

21 January 2018

1 reference

Response of infantile spasms to levetiracetam

21 January 2018

1 reference

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

21 January 2018

1 reference

Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures

21 January 2018

1 reference

Assessment of a dose-response relationship of levetiracetam.

21 January 2018

1 reference

Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.

21 January 2018

1 reference

Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study

21 January 2018

1 reference

Levetiracetam as a treatment option in non-convulsive status epilepticus

21 January 2018

1 reference

Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus

21 January 2018

1 reference

Intravenous levetiracetam as treatment for status epilepticus.

21 January 2018

1 reference

Two years of experience in the treatment of status epilepticus with intravenous levetiracetam.

21 January 2018

1 reference

Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus

21 January 2018

1 reference

Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus

21 January 2018

1 reference

Safety and efficacy of levetiracetam for critically ill patients with seizures

21 January 2018

1 reference

Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials

21 January 2018

1 reference

Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery

21 January 2018

1 reference

Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage

21 January 2018

1 reference

Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats

21 January 2018

1 reference

Effect of levetiracetam on visual-spatial memory following status epilepticus

21 January 2018

1 reference

Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia

21 January 2018

1 reference

Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome

21 January 2018

1 reference

Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome.

21 January 2018

1 reference

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

21 January 2018

1 reference

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

21 January 2018

1 reference

Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia.

21 January 2018

1 reference

Levetiracetam in spinal cord injury pain: a randomized controlled trial.

21 January 2018

1 reference

Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.

21 January 2018

1 reference

Levetiracetam for managing neurologic and psychiatric disorders

21 January 2018

1 reference

Levetiracetam-induced thrombocytopenia

21 January 2018

1 reference

Levetiracetam-induced pancytopenia.

21 January 2018

1 reference

Levetiracetam as a possible cause of fulminant liver failure

21 January 2018

1 reference

Levetiracetam-induced parkinsonism in a Huntington disease patient

21 January 2018

1 reference

Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

21 January 2018

1 reference

Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results

21 January 2018

1 reference

Suicidality and antiepileptic drugs: is there a link?

21 January 2018

1 reference

Levetiracetam concentrations in serum and in breast milk at birth and during lactation

21 January 2018

1 reference

Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

21 January 2018

1 reference

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

21 January 2018

1 reference

Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy

21 January 2018

1 reference

21 January 2018

Seletracetam (UCB 44212)

1 reference

SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

21 January 2018

1 reference

Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy

21 January 2018

1 reference

Suicidal ideation in epilepsy and levetiracetam therapy

21 January 2018

1 reference

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.10.3

1 reference

22 August 2017

1 reference